Jhony Alberto De La Cruz Vargas
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Jhony Alberto De La Cruz Vargas has a total of 650 co-authors. Here are the top co-authors by number of shared publications:
- Lucy Elena Correa Lopez
Instituto de Investigaciones en Ciencias Biomédicas, Universidad Ricardo Palma, Lima, Perú
36 shared publications - Víctor Juan Vera-Ponce
Facultad de Medicina (FAMED), Universidad Nacional Toribio Rodríguez de Mendoza de Amazonas (UNTRM), Chachapoyas, Peru
31 shared publications - Willy Ramos
Instituto de Investigaciones en Ciencias Biomédicas, Universidad Ricardo Palma, Lima, Perú
26 shared publications - Jenny Raquel Torres-Malca
Universidad Ricardo Palma
22 shared publications - Fiorella E. Zuzunaga Montoya
Facultad de Medicina (FAMED), Universidad Nacional Toribio Rodríguez de Mendoza de Amazonas (UNTRM), Amazonas, Perú
17 shared publications - Joan A. Loayza-Castro
Instituto de Investigación de Enfermedades Tropicales, Universidad Nacional Toribio Rodríguez de Mendoza de Amazonas (UNTRM), Amazonas, Perú
16 shared publications
Latest Publications
- Open Access
- 14 September 2026
- Published by Instituto Nacional de Salud (Peru) in Revista Peruana de Medicina Experimental Y Salud Pública
- p. 397-401
Radón residencial en el Perú: desafíos para la vigilancia sanitaria y la prevención del cáncer de pulmón
El radón es un carcinógeno pulmonar reconocido a nivel mundial y uno de los principales factores de riesgo de cáncer de pulmón en personas no fumadoras. En el Perú, la evidencia reciente indica concentraciones elevadas de radón en viviendas de Lima Metropolitana y una posible contribución al incremento del cáncer de pulmón, especialmente en mujeres, aunque la evidencia nacional proviene principalmente de estudios ecológicos y aún es insuficiente para establecer causalidad. Persisten brechas normativas, técnicas y de vigilancia que dificultan su control. Este artículo especial presenta una revisión narrativa de la evidencia internacional y nacional y tiene como objetivo examinar la situación actual de la exposición al radón en el Perú, identificar las brechas regulatorias y de vigilancia que limitan su control y proponer medidas específicas de mitigación alineadas con recomendaciones internacionales.
- 14 September 2026
- Published by Instituto Nacional de Salud (Peru) in Revista Peruana de Medicina Experimental Y Salud Pública
- p. 397-401
Open AccessRadón residencial en el Perú: desafíos para la vigilancia sanitaria y la prevención del cáncer de pulmón
El radón es un carcinógeno pulmonar reconocido a nivel mundial y uno de los principales factores de riesgo de cáncer de pulmón en personas no fumadoras. En el Perú, la evidencia reciente indica concentraciones elevadas de radón en viviendas de Lima Metropolitana y una posible contribución al incremento del cáncer de pulmón, especialmente en mujeres, aunque la evidencia nacional proviene principalmente de estudios ecológicos y aún es insuficiente para establecer causalidad. Persisten brechas normativas, técnicas y de vigilancia que dificultan su control. Este artículo especial presenta una revisión narrativa de la evidencia internacional y nacional y tiene como objetivo examinar la situación actual de la exposición al radón en el Perú, identificar las brechas regulatorias y de vigilancia que limitan su control y proponer medidas específicas de mitigación alineadas con recomendaciones internacionales.
- 30 June 2025
- Published by Instituto de Investigacion en Ciencias Biomedicas in Revista de la Facultad de Medicina Humana
- Vol. 25 (2) , 61-68
Asociación entre los estilos de vida y el locus de control en salud en estudiantes de medicina humana
Introduction: Health locus of control refers to an individual's perception of the extent to which they can influence their own health status. It is classified as internal when the person assumes responsibility for their health, or external when control is attributed to chance or other people. These beliefs directly affect self-care practices and lifestyle decisions. Objective: To determine the association between the dimensions of health locus of control (internality, powerful others, and chance) and lifestyle habits among university students in Lima, Peru. Methodology: A cross-sectional analytical study was conducted between March and April 2023 using an online survey. A total of 918 students from a private university participated, selected through non-probabilistic consecutive sampling. Validated instruments were used to assess lifestyle (nine dimensions) and health locus of control (three dimensions). Descriptive and bivariate analyses were carried out using the Chi-square test. Results: A total of 55.2% of participants reported having an unhealthy lifestyle. The internality dimension was significantly associated with sex (p<0.001), age (p=0.043), and place of residence (p=0.001). The dimensions of powerful others and chance were significantly associated with lifestyle (p=0.003 and p=0.001, respectively). Conclusions: An internal health locus of control is associated with healthier behaviors, while an external locus, particularly the chance dimension, is linked to riskier lifestyle patterns. These findings underscore the importance of incorporating psychological factors into health promotion strategies targeted at university populations Keywords: Lifestyle, internal-external control, university students (Source: MESH NLM).
- 30 June 2025
- Published by Instituto de Investigacion en Ciencias Biomedicas in Revista de la Facultad de Medicina Humana
- Vol. 25 (2) , 61-68
Asociación entre los estilos de vida y el locus de control en salud en estudiantes de medicina humana
Introduction: Health locus of control refers to an individual's perception of the extent to which they can influence their own health status. It is classified as internal when the person assumes responsibility for their health, or external when control is attributed to chance or other people. These beliefs directly affect self-care practices and lifestyle decisions. Objective: To determine the association between the dimensions of health locus of control (internality, powerful others, and chance) and lifestyle habits among university students in Lima, Peru. Methodology: A cross-sectional analytical study was conducted between March and April 2023 using an online survey. A total of 918 students from a private university participated, selected through non-probabilistic consecutive sampling. Validated instruments were used to assess lifestyle (nine dimensions) and health locus of control (three dimensions). Descriptive and bivariate analyses were carried out using the Chi-square test. Results: A total of 55.2% of participants reported having an unhealthy lifestyle. The internality dimension was significantly associated with sex (p<0.001), age (p=0.043), and place of residence (p=0.001). The dimensions of powerful others and chance were significantly associated with lifestyle (p=0.003 and p=0.001, respectively). Conclusions: An internal health locus of control is associated with healthier behaviors, while an external locus, particularly the chance dimension, is linked to riskier lifestyle patterns. These findings underscore the importance of incorporating psychological factors into health promotion strategies targeted at university populations Keywords: Lifestyle, internal-external control, university students (Source: MESH NLM).
- Open Access
- 11 June 2025
- Published by MDPI AG in Current Oncology
- Vol. 32 (6) , 344
Prognostic Relevance of Inflammatory Cytokines Il-6 and TNF-Alpha in Patients with Breast Cancer: A Systematic Review and Meta-Analysis
Although cytokines mediate inflammation and inflammation facilitates cancer progression, few studies have evaluated the association between specific cytokines and the prognostic value of breast cancer. Therefore, this study aims to address the following question: What is the prognostic relevance of serum IL-6 and TNF-alpha levels on overall survival and treatment response in women with breast cancer? A systematic review and meta-analysis of cohort studies was conducted. The databases consulted included PubMed/Medline, Web of Science, and EMBASE. A total of 1748 articles were identified, of which 10 were included in the review. A significant association was found between elevated levels of IL-6 and TNF-alpha with poor overall survival and poor treatment response. The meta-analysis showed an HR of 3.74 (95% CI: 1.84–7.6) for elevated IL-6 with high heterogeneity (I2: 61%; p = 0.07) and an HR of 3.13 (95% CI: 1.57–6.23) for TNF-alpha with low heterogeneity (I2: 0%; p = 0.9). The overall response rate was 75% (95% CI: 31–100%; I2: 92%). In conclusion, IL-6 and TNF-alpha emerge as prognostic inflammatory biomarkers in women with breast cancer and are associated with poor survival and poor treatment response. This study highlights the need to establish an international consensus on cutoff points and standardized determination methods to implement these biomarkers in clinical practice.
- 11 June 2025
- Published by MDPI AG in Current Oncology
- Vol. 32 (6) , 344
Open AccessPrognostic Relevance of Inflammatory Cytokines Il-6 and TNF-Alpha in Patients with Breast Cancer: A Systematic Review and Meta-Analysis
Although cytokines mediate inflammation and inflammation facilitates cancer progression, few studies have evaluated the association between specific cytokines and the prognostic value of breast cancer. Therefore, this study aims to address the following question: What is the prognostic relevance of serum IL-6 and TNF-alpha levels on overall survival and treatment response in women with breast cancer? A systematic review and meta-analysis of cohort studies was conducted. The databases consulted included PubMed/Medline, Web of Science, and EMBASE. A total of 1748 articles were identified, of which 10 were included in the review. A significant association was found between elevated levels of IL-6 and TNF-alpha with poor overall survival and poor treatment response. The meta-analysis showed an HR of 3.74 (95% CI: 1.84–7.6) for elevated IL-6 with high heterogeneity (I2: 61%; p = 0.07) and an HR of 3.13 (95% CI: 1.57–6.23) for TNF-alpha with low heterogeneity (I2: 0%; p = 0.9). The overall response rate was 75% (95% CI: 31–100%; I2: 92%). In conclusion, IL-6 and TNF-alpha emerge as prognostic inflammatory biomarkers in women with breast cancer and are associated with poor survival and poor treatment response. This study highlights the need to establish an international consensus on cutoff points and standardized determination methods to implement these biomarkers in clinical practice.
- Open Access
- 1 June 2025
- Published by Taylor & Francis in ClinicoEconomics and Outcomes Research
- Vol. ume 17, 429-436
The Social Cost of Nasal Sequelae in Patients with Cleft Lip and Palate in a Peruvian University Dental Clinic
Objective: To estimate the social cost of nasal sequelae in patients with cleft lip and palate (CL/P) treated in a Peruvian university dental clinic. Methods: This is a cross-sectional study. The sample consisted of thirty patients over 18 years of age with nasal sequelae due to CL/P. This study conducted a partial economic analysis from a social perspective, by using the following questionnaires: ENAHO-Peru to assess sociodemographic variables, the Instituto de Salud del Niño - San Borja care guidelines and its tariff schedule to estimate health care costs, the Rhinoplasty Outcome Evaluation (ROE) scale to assess quality of life about the nasal sequela, and the “willingness to pay” (WTP) technique to calculate the monetary cost of the sequela from the patients’ perspective. Costs in soles, where the exchange rate was: 1 USD = S/3.878. Results: A total of 30 CL/P patients, who agreed to participate, were evaluated. Most of the patients were male (70.0%), aged 18– 39 years (73.0%), single (93.4%), students (73.4%), and had secondary education (50.0%). Additionally, most were attended with Seguro Integral de Salud (46.7%), most had no daily income (50.0%), and the average quality of life score was 8.1. The highest direct cost reported was dental treatment (S/5756.89 ± S/359.22) and hospitalization (S/5013.60 ± S/880.15), statistically significant (p< 0.05). The highest indirect cost was reported for absenteeism with a mean of 5288.6 ± 1280.23 (p< 0.05). Regarding direct, indirect, and intangible costs in the treatment of nasal sequelae due to CL/P, the lowest median (S/6000.00) was found in intangible costs, with significant differences (p< 0.05). Conclusion: About half of the social cost (12,000 Peruvian soles = 3094 US dollars) was assumed by the patients, a prohibitive cost considering that most of them come from low socio-economic backgrounds. Plain Language Summary: Cleft lip and palate (CL/P) cause a disproportionate economic burden. Despite advances in surgery, these patients very often develop sequelae.No health insurance in Peru covers rhinoplasty, as it is considered a surgery to improve the image and not necessarily function. This research estimated that the patients with CL/P bear almost half of the social cost. This could have implications for state insurance mechanisms that could improve coverage of surgical procedures aimed at improving the sequelae of CL/P, which would reduce the social cost borne by patients.
- 1 June 2025
- Published by Taylor & Francis in ClinicoEconomics and Outcomes Research
- Vol. ume 17, 429-436
Open AccessThe Social Cost of Nasal Sequelae in Patients with Cleft Lip and Palate in a Peruvian University Dental Clinic
Objective: To estimate the social cost of nasal sequelae in patients with cleft lip and palate (CL/P) treated in a Peruvian university dental clinic. Methods: This is a cross-sectional study. The sample consisted of thirty patients over 18 years of age with nasal sequelae due to CL/P. This study conducted a partial economic analysis from a social perspective, by using the following questionnaires: ENAHO-Peru to assess sociodemographic variables, the Instituto de Salud del Niño - San Borja care guidelines and its tariff schedule to estimate health care costs, the Rhinoplasty Outcome Evaluation (ROE) scale to assess quality of life about the nasal sequela, and the “willingness to pay” (WTP) technique to calculate the monetary cost of the sequela from the patients’ perspective. Costs in soles, where the exchange rate was: 1 USD = S/3.878. Results: A total of 30 CL/P patients, who agreed to participate, were evaluated. Most of the patients were male (70.0%), aged 18– 39 years (73.0%), single (93.4%), students (73.4%), and had secondary education (50.0%). Additionally, most were attended with Seguro Integral de Salud (46.7%), most had no daily income (50.0%), and the average quality of life score was 8.1. The highest direct cost reported was dental treatment (S/5756.89 ± S/359.22) and hospitalization (S/5013.60 ± S/880.15), statistically significant (p< 0.05). The highest indirect cost was reported for absenteeism with a mean of 5288.6 ± 1280.23 (p< 0.05). Regarding direct, indirect, and intangible costs in the treatment of nasal sequelae due to CL/P, the lowest median (S/6000.00) was found in intangible costs, with significant differences (p< 0.05). Conclusion: About half of the social cost (12,000 Peruvian soles = 3094 US dollars) was assumed by the patients, a prohibitive cost considering that most of them come from low socio-economic backgrounds. Plain Language Summary: Cleft lip and palate (CL/P) cause a disproportionate economic burden. Despite advances in surgery, these patients very often develop sequelae.No health insurance in Peru covers rhinoplasty, as it is considered a surgery to improve the image and not necessarily function. This research estimated that the patients with CL/P bear almost half of the social cost. This could have implications for state insurance mechanisms that could improve coverage of surgical procedures aimed at improving the sequelae of CL/P, which would reduce the social cost borne by patients.
- Open Access
- 11 December 2024
- Published by MDPI AG in Microbiology Research
- Vol. 15 (4) , 2650-2660
Acinetobacter baumannii Co-Resistant to Extended Spectrum Beta-Lactamases and Carbapenemases in Six Peruvian Hospital Centers
Objectives: The aim of this study was to describe the phenotypic and molecular characteristics of Acinetobacter baumannii isolates carrying resistance genes to beta-lactams and carbapenems in six Peruvian public hospital centers. Materials and methods: The susceptibility of bacterial isolates was determined using the automated MicroScan system, with interpretation according to the M100 S30 CLSI 2020. Resistance genes were identified by conventional polymerase chain reaction (PCR), and PCR products were visualized by 1% agarose gel electrophoresis. Results: Nine strains (TRU1, PM1, PM2, CUS1, CUS2, CUS3, CAL1, CAL2 and CAL3) out of a total of 21 strains in the study were reactivated, showing resistance of 77.8% to imipenem, ciprofloxacin and cefepime, followed by 66.7% resistance to meropenem and ceftazidime, indicating marked multidrug resistance. In addition, the detection of the group A beta-lactamase genes blaCTX-M and blaTEM was confirmed, showing co-resistance in strains CUS1, CUS2 and CUS3, despite their unusual presence in this pathogen, also determined by the presence of the group D carbapenemase blaOXA in strain CUS3, the only strain to show co-resistance of the three groups. Conclusion: The prevalence of Acinetobacter baumannii resistant to extended-spectrum beta-lactamases and carbapenemases in Peruvian public centers represents a critical challenge for the treatment of infections. Rigorous surveillance, infection control strategies, and the development of alternative therapies are urgently needed to address this growing bacterial resistance.
- 11 December 2024
- Published by MDPI AG in Microbiology Research
- Vol. 15 (4) , 2650-2660
Open AccessAcinetobacter baumannii Co-Resistant to Extended Spectrum Beta-Lactamases and Carbapenemases in Six Peruvian Hospital Centers
Objectives: The aim of this study was to describe the phenotypic and molecular characteristics of Acinetobacter baumannii isolates carrying resistance genes to beta-lactams and carbapenems in six Peruvian public hospital centers. Materials and methods: The susceptibility of bacterial isolates was determined using the automated MicroScan system, with interpretation according to the M100 S30 CLSI 2020. Resistance genes were identified by conventional polymerase chain reaction (PCR), and PCR products were visualized by 1% agarose gel electrophoresis. Results: Nine strains (TRU1, PM1, PM2, CUS1, CUS2, CUS3, CAL1, CAL2 and CAL3) out of a total of 21 strains in the study were reactivated, showing resistance of 77.8% to imipenem, ciprofloxacin and cefepime, followed by 66.7% resistance to meropenem and ceftazidime, indicating marked multidrug resistance. In addition, the detection of the group A beta-lactamase genes blaCTX-M and blaTEM was confirmed, showing co-resistance in strains CUS1, CUS2 and CUS3, despite their unusual presence in this pathogen, also determined by the presence of the group D carbapenemase blaOXA in strain CUS3, the only strain to show co-resistance of the three groups. Conclusion: The prevalence of Acinetobacter baumannii resistant to extended-spectrum beta-lactamases and carbapenemases in Peruvian public centers represents a critical challenge for the treatment of infections. Rigorous surveillance, infection control strategies, and the development of alternative therapies are urgently needed to address this growing bacterial resistance.
- Open Access
- 31 October 2024
- Published by Instituto de Investigacion en Ciencias Biomedicas in Revista de la Facultad de Medicina Humana
- Vol. 24 (4) , 12-15
El Grupo de Estudio Latinoamericano de Linfomas (GELL): Un Modelo de Investigación Colaborativa en América Latina
Introduction Collaborative health research has proven to be an effective approach to addressing regional and international challenges in the diagnosis, treatment, and management of diseases (1–4). In Latin America, a region characterized by geographic, socioeconomic, and epidemiological diversity, the creation of research networks is essential to unify efforts and generate knowledge applicable locally and internationally (1–4). In this context, the Latin American Lymphoma Study Group (GELL) emerges as a key player in lymphoma research—a family of hematologic cancers with high clinical and molecular heterogeneity. Origins and Structure of GELL Founded in 2018, GELL is a collaborative research network comprising 14 Latin American countries, supported by prestigious international institutions such as the Dana Farber Institute, MD Anderson Cancer Center, and Tampa General Hospital. The group’s primary objective is to conduct multicenter studies that provide high-quality epidemiological, clinical, and molecular data on various lymphoma subtypes. GELL's leadership includes Dr. Brady Beltrán (Peru) as president, Dr. María Torres (Venezuela) as vice president, and Dr. Denisse Castro (Peru) as treasurer. This organizational structure enables efficient coordination among member countries, ensuring the planning and execution of clinical and translational studies across the region. Objectives and Achievements of GELL One of GELL's main objectives is to determine the epidemiology of different lymphoma subtypes in Latin America, including diffuse large B-cell lymphoma (DLBCL), follicular lymphoma, nasal-type T/NK-cell lymphoma, and Epstein-Barr virus (EBV)-associated lymphoma. The group also aims to develop retrospective and prospective studies on inflammatory biomarkers and novel prognostic scores (5–7). These studies help identify risk factors and clinical parameters that predict treatment response and prognosis in lymphoma patients. To date, GELL has collected data on more than 6,400 patients in retrospective studies, including: 1,500 patients with DLBCL (6,8). 1,000 patients with peripheral T-cell lymphoma (PTCL-NOS) (9). 800 patients with follicular lymphoma (10). 2,000 patients with adult T-cell leukemia/lymphoma (ATLL) (11). These retrospective studies are crucial for generating hypotheses that guide future prospective studies, contributing to a better understanding of lymphomas in the region. Scientific Production and Knowledge Dissemination GELL has achieved remarkable scientific output, contributing 37 works that include: 6 articles published in high-impact journals. 30 posters presented at international conferences such as ASH, EHA, and the World HTLV-1 Congress. 4 oral sessions at international scientific events. Among its most significant scientific achievements is the multicenter validation of the prognostic value of the neutrophil-to-lymphocyte ratio in DLBCL patients (12), published in collaboration with other international institutions. Additionally, GELL has developed consensus on relevant topics such as the management of patients with unspecified peripheral T-cell lymphoma (PTCL-NOS), which is in the process of publication, and the impact of COVID-19 on lymphoma patients (13). The impact of GELL's scientific production is measured not only in terms of publications and presentations but also in its ability to influence clinical practice at the regional level. The creation of consensuses and participation in clinical trials ensure that GELL's findings are immediately applicable to patient care in Latin America. Future Projects and GELL's Expansion GELL is not content with its achievements and continues to expand its horizons towards new research projects. One of the most ambitious projects underway is a molecular study on the genetic profile of DLBCL in Latin America, which will analyze over 400 genes using the Foundation One–Heme platform. This will be the first study of its kind in the region, providing a detailed understanding of the genetic alterations characterizing lymphomas in Latin American patients. Another significant project involves conducting prospective clinical trials on nasal-type T/NK-cell lymphoma and a meta-analysis on inflammatory biomarkers in lymphomas. These studies not only contribute to advancing scientific knowledge but also allow patients access to innovative treatments through clinical trials, promoting equity in access to advanced therapies. International Collaboration GELL has established collaborations with research groups from Japan, Brazil, and Italy, enabling it to build one of the largest global databases on T-cell lymphomas and EBV-associated DLBCL. These collaborations reflect the growing relevance of studies conducted in Latin America and position GELL as a global leader in lymphoma research. Conclusion The Latin American Lymphoma Study Group (GELL) has demonstrated that scientific collaboration in Latin America can generate valuable knowledge applicable globally. Its efforts to unify data from multiple countries, conduct prospective and retrospective studies, and promote participation in clinical trials have significantly improved the care of lymphoma patients in the region. With ambitious projects on the horizon, such as the molecular analysis of DLBCL and new clinical trials, GELL is well-positioned to continue leading lymphoma research in Latin America and beyond.
- 31 October 2024
- Published by Instituto de Investigacion en Ciencias Biomedicas in Revista de la Facultad de Medicina Humana
- Vol. 24 (4) , 12-15
Open AccessEl Grupo de Estudio Latinoamericano de Linfomas (GELL): Un Modelo de Investigación Colaborativa en América Latina
Introduction Collaborative health research has proven to be an effective approach to addressing regional and international challenges in the diagnosis, treatment, and management of diseases (1–4). In Latin America, a region characterized by geographic, socioeconomic, and epidemiological diversity, the creation of research networks is essential to unify efforts and generate knowledge applicable locally and internationally (1–4). In this context, the Latin American Lymphoma Study Group (GELL) emerges as a key player in lymphoma research—a family of hematologic cancers with high clinical and molecular heterogeneity. Origins and Structure of GELL Founded in 2018, GELL is a collaborative research network comprising 14 Latin American countries, supported by prestigious international institutions such as the Dana Farber Institute, MD Anderson Cancer Center, and Tampa General Hospital. The group’s primary objective is to conduct multicenter studies that provide high-quality epidemiological, clinical, and molecular data on various lymphoma subtypes. GELL's leadership includes Dr. Brady Beltrán (Peru) as president, Dr. María Torres (Venezuela) as vice president, and Dr. Denisse Castro (Peru) as treasurer. This organizational structure enables efficient coordination among member countries, ensuring the planning and execution of clinical and translational studies across the region. Objectives and Achievements of GELL One of GELL's main objectives is to determine the epidemiology of different lymphoma subtypes in Latin America, including diffuse large B-cell lymphoma (DLBCL), follicular lymphoma, nasal-type T/NK-cell lymphoma, and Epstein-Barr virus (EBV)-associated lymphoma. The group also aims to develop retrospective and prospective studies on inflammatory biomarkers and novel prognostic scores (5–7). These studies help identify risk factors and clinical parameters that predict treatment response and prognosis in lymphoma patients. To date, GELL has collected data on more than 6,400 patients in retrospective studies, including: 1,500 patients with DLBCL (6,8). 1,000 patients with peripheral T-cell lymphoma (PTCL-NOS) (9). 800 patients with follicular lymphoma (10). 2,000 patients with adult T-cell leukemia/lymphoma (ATLL) (11). These retrospective studies are crucial for generating hypotheses that guide future prospective studies, contributing to a better understanding of lymphomas in the region. Scientific Production and Knowledge Dissemination GELL has achieved remarkable scientific output, contributing 37 works that include: 6 articles published in high-impact journals. 30 posters presented at international conferences such as ASH, EHA, and the World HTLV-1 Congress. 4 oral sessions at international scientific events. Among its most significant scientific achievements is the multicenter validation of the prognostic value of the neutrophil-to-lymphocyte ratio in DLBCL patients (12), published in collaboration with other international institutions. Additionally, GELL has developed consensus on relevant topics such as the management of patients with unspecified peripheral T-cell lymphoma (PTCL-NOS), which is in the process of publication, and the impact of COVID-19 on lymphoma patients (13). The impact of GELL's scientific production is measured not only in terms of publications and presentations but also in its ability to influence clinical practice at the regional level. The creation of consensuses and participation in clinical trials ensure that GELL's findings are immediately applicable to patient care in Latin America. Future Projects and GELL's Expansion GELL is not content with its achievements and continues to expand its horizons towards new research projects. One of the most ambitious projects underway is a molecular study on the genetic profile of DLBCL in Latin America, which will analyze over 400 genes using the Foundation One–Heme platform. This will be the first study of its kind in the region, providing a detailed understanding of the genetic alterations characterizing lymphomas in Latin American patients. Another significant project involves conducting prospective clinical trials on nasal-type T/NK-cell lymphoma and a meta-analysis on inflammatory biomarkers in lymphomas. These studies not only contribute to advancing scientific knowledge but also allow patients access to innovative treatments through clinical trials, promoting equity in access to advanced therapies. International Collaboration GELL has established collaborations with research groups from Japan, Brazil, and Italy, enabling it to build one of the largest global databases on T-cell lymphomas and EBV-associated DLBCL. These collaborations reflect the growing relevance of studies conducted in Latin America and position GELL as a global leader in lymphoma research. Conclusion The Latin American Lymphoma Study Group (GELL) has demonstrated that scientific collaboration in Latin America can generate valuable knowledge applicable globally. Its efforts to unify data from multiple countries, conduct prospective and retrospective studies, and promote participation in clinical trials have significantly improved the care of lymphoma patients in the region. With ambitious projects on the horizon, such as the molecular analysis of DLBCL and new clinical trials, GELL is well-positioned to continue leading lymphoma research in Latin America and beyond.
- Open Access
- 31 October 2024
- Published by Instituto de Investigacion en Ciencias Biomedicas in Revista de la Facultad de Medicina Humana
- Vol. 24 (4) , 7-11
Ricardo Palma University awards the distinction of "Doctor Honoris Causa" to Prof. Dr. Herbert
The "Doctor Honoris Causa" is the highest honorary title awarded by Ricardo Palma University to eminent individuals. It is conferred with great care and rigor by our institution to highly distinguished figures from national and international spheres, whose work and personal achievements honor culture, science, and humanity. Based on the remarkable academic trajectory ofDoctor Bob Pinedo, his invaluable scientific contributions, and, notably, his distinguished spirit of collaboration with Peru, Latin America and the Caribbean, and notably with our university, a ceremony was held in which Universidad Ricardo Palmaawarded him the academic distinction of Doctor Honoris Causa, during the 2024 International Congress on Cancer and Public Health. Additionally, during the same ceremony, he received recognition and an award from the Colegio Médico del Perú.
- 31 October 2024
- Published by Instituto de Investigacion en Ciencias Biomedicas in Revista de la Facultad de Medicina Humana
- Vol. 24 (4) , 7-11
Open AccessRicardo Palma University awards the distinction of "Doctor Honoris Causa" to Prof. Dr. Herbert
The "Doctor Honoris Causa" is the highest honorary title awarded by Ricardo Palma University to eminent individuals. It is conferred with great care and rigor by our institution to highly distinguished figures from national and international spheres, whose work and personal achievements honor culture, science, and humanity. Based on the remarkable academic trajectory ofDoctor Bob Pinedo, his invaluable scientific contributions, and, notably, his distinguished spirit of collaboration with Peru, Latin America and the Caribbean, and notably with our university, a ceremony was held in which Universidad Ricardo Palmaawarded him the academic distinction of Doctor Honoris Causa, during the 2024 International Congress on Cancer and Public Health. Additionally, during the same ceremony, he received recognition and an award from the Colegio Médico del Perú.
- Open Access
- 23 September 2024
- Published by SAGE Publications in The International Journal of Biological Markers
- Vol. 39 (4) , 277-283
Inflammatory markers related to survival in breast cancer patients: Peru
Introduction: Breast cancer is a disease with high global prevalence. Clinical inflammatory biomarkers have been proposed as prognostic indicators in oncology. This research aims to determine the relationship between inflammatory markers and overall survival in breast cancer patients from four representative hospitals in Lima, Peru. Methods: This is a multicentric, analytical, longitudinal retrospective cohort study with survival analysis in female patients with breast cancer, from 2015 to 2020, who had received at least one complete treatment regimen. The dependent variable was overall survival, and the independent variables were inflammatory markers neutrophil lymphocyte ratio, platelet lymphocyte ratio (PLR), albumin, and red cell distribution width; intervening variables included age, clinical stage, molecular subtype, and other known prognostic factors. The Kaplan–Meier method was applied to generate survival curves with the Log-Rank test, and finally, Cox regression, to find crude and adjusted hazard ratios (HR). Results: Of 705 evaluated patients, 618 were analyzed. The mean age was 56.6 ± 12.3 years, 18.0% of patients were pure HER2 positive, 39.3% luminal A, 29.9% luminal B, 11.0% triple-negative, and 81.4% showed overweight and obesity. The average overall survival was 51.1 months. In the multivariate analysis, factors significantly related to lower overall survival were PLR > 150 (adjusted HR: 2.33; 95% confidence interval (CI): 1.22, 4.44) and stage III (adjusted HR: 4.15; 95% CI: 1.35, 12.83). Conclusions: The Elevated Platelet-Lymphocyte Index and advanced clinical stage were associated with lower overall survival in breast cancer patients. Furthermore, PLR >150 proved to be an independent prognostic factor for mortality.
- 23 September 2024
- Published by SAGE Publications in The International Journal of Biological Markers
- Vol. 39 (4) , 277-283
Open AccessInflammatory markers related to survival in breast cancer patients: Peru
Introduction: Breast cancer is a disease with high global prevalence. Clinical inflammatory biomarkers have been proposed as prognostic indicators in oncology. This research aims to determine the relationship between inflammatory markers and overall survival in breast cancer patients from four representative hospitals in Lima, Peru. Methods: This is a multicentric, analytical, longitudinal retrospective cohort study with survival analysis in female patients with breast cancer, from 2015 to 2020, who had received at least one complete treatment regimen. The dependent variable was overall survival, and the independent variables were inflammatory markers neutrophil lymphocyte ratio, platelet lymphocyte ratio (PLR), albumin, and red cell distribution width; intervening variables included age, clinical stage, molecular subtype, and other known prognostic factors. The Kaplan–Meier method was applied to generate survival curves with the Log-Rank test, and finally, Cox regression, to find crude and adjusted hazard ratios (HR). Results: Of 705 evaluated patients, 618 were analyzed. The mean age was 56.6 ± 12.3 years, 18.0% of patients were pure HER2 positive, 39.3% luminal A, 29.9% luminal B, 11.0% triple-negative, and 81.4% showed overweight and obesity. The average overall survival was 51.1 months. In the multivariate analysis, factors significantly related to lower overall survival were PLR > 150 (adjusted HR: 2.33; 95% confidence interval (CI): 1.22, 4.44) and stage III (adjusted HR: 4.15; 95% CI: 1.35, 12.83). Conclusions: The Elevated Platelet-Lymphocyte Index and advanced clinical stage were associated with lower overall survival in breast cancer patients. Furthermore, PLR >150 proved to be an independent prognostic factor for mortality.
- Open Access
- 6 September 2024
- Published by Elsevier in Clinical Nutrition Open Science
- Vol. 58, 1-9
Malnutrition and other factors associated with hospitalization in older adults treated at the naval medical center of Callao - Peru
- 6 September 2024
- Published by Elsevier in Clinical Nutrition Open Science
- Vol. 58, 1-9
Open AccessMalnutrition and other factors associated with hospitalization in older adults treated at the naval medical center of Callao - Peru
- Open Access
- 25 July 2024
- Published by Springer Nature in Scientific Reports
- Vol. 14 (1) , 1-9
Pan-immune-inflammation value and survival in patients with breast cancer from a Peruvian reference hospital
The pan-immune-inflammation value (PIV), calculated as (neutrophil × platelet × monocyte)/lymphocyte count, may be useful for estimating survival in breast cancer patients. To determine the prognostic value of PIV for overall survival in breast cancer patients in Lima, Peru. A retrospective cohort study was conducted. 97 breast cancer patients diagnosed between January 2010 and December 2016 had their medical records analyzed. The primary dependent variable was overall survival, and the key independent variable was the PIV, divided into high (≥ 310) and low (< 310) groups. Patient data included demographics, treatment protocols and other clinical variables. Statistical analysis involved Kaplan–Meier survival curves and Cox proportional hazards modeling. Patients with a PIV ≥ 310 had significantly lower 5-year survival functions (p = 0.004). Similar significant differences in survival were observed for clinical stage III-IV (p = 0.015), hemoglobin levels < 12 mg/Dl (p = 0.007), histological grade (p = 0.019), and nuclear grade (p < 0.001); however, molecular classification did not show a significant survival difference (p = 0.371). The adjusted Hazard Ratios showed that PIV ≥ 310 was significantly associated with poor outcome (5.08, IC95%: 1.52–16.92). While clinical stage and hemoglobin levels were associated with survival in the unadjusted model. These factors did not maintain significance after adjustment. PIV is an independent predictor of reduced survival in Peruvian breast cancer patients.
- 25 July 2024
- Published by Springer Nature in Scientific Reports
- Vol. 14 (1) , 1-9
Open AccessPan-immune-inflammation value and survival in patients with breast cancer from a Peruvian reference hospital
The pan-immune-inflammation value (PIV), calculated as (neutrophil × platelet × monocyte)/lymphocyte count, may be useful for estimating survival in breast cancer patients. To determine the prognostic value of PIV for overall survival in breast cancer patients in Lima, Peru. A retrospective cohort study was conducted. 97 breast cancer patients diagnosed between January 2010 and December 2016 had their medical records analyzed. The primary dependent variable was overall survival, and the key independent variable was the PIV, divided into high (≥ 310) and low (< 310) groups. Patient data included demographics, treatment protocols and other clinical variables. Statistical analysis involved Kaplan–Meier survival curves and Cox proportional hazards modeling. Patients with a PIV ≥ 310 had significantly lower 5-year survival functions (p = 0.004). Similar significant differences in survival were observed for clinical stage III-IV (p = 0.015), hemoglobin levels < 12 mg/Dl (p = 0.007), histological grade (p = 0.019), and nuclear grade (p < 0.001); however, molecular classification did not show a significant survival difference (p = 0.371). The adjusted Hazard Ratios showed that PIV ≥ 310 was significantly associated with poor outcome (5.08, IC95%: 1.52–16.92). While clinical stage and hemoglobin levels were associated with survival in the unadjusted model. These factors did not maintain significance after adjustment. PIV is an independent predictor of reduced survival in Peruvian breast cancer patients.